ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,255.20
1.29%
Dow Jones
40,421.36
0.33%
Brent Oil
81.785
0.33%
Bitcoin
67,337.89
-0.39%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NeuroBo Pharmaceuticals Inc (NRBO)

  7. NeuroBo Pharmaceuticals Inc (NRBO) News

NRBO

NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRBO
DateTimeSourceHeadlineSymbolCompany
07/18/20248:21AMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/16/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
07/10/202411:11AMEdgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/26/20249:06AMPR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/25/20245:08PMPR Newswire (US)NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/24/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/22/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical ModelsNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/07/20247:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRBONeuroBo Pharmaceuticals Inc
06/07/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
05/22/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
05/22/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, AloneNASDAQ:NRBONeuroBo Pharmaceuticals Inc
05/09/20249:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRBONeuroBo Pharmaceuticals Inc
05/09/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
05/09/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/30/20248:01AMPR Newswire (US)NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in JuneNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/17/20248:05AMPR Newswire (US)NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
04/01/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/28/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/13/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/04/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial OfficerNASDAQ:NRBONeuroBo Pharmaceuticals Inc
03/04/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/29/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/29/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/14/20248:52AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/12/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor ConferenceNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/01/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
02/01/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of ObesityNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/18/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/18/20248:01AMPR Newswire (US)NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASHNASDAQ:NRBONeuroBo Pharmaceuticals Inc
01/09/20248:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRBONeuroBo Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NRBO

Your Recent History

USOTC
ITUP
Interups (CE)
USOTC
IDVV
International Endeavors (PK)
NYSE
AMC
AMC Entertainment
USOTC
MGON
Megola (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
GRLT
Grillit (PK)
USOTC
CNNA
Cann American (CE)
USOTC
NBRI
North Bay Resources (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
CGAC
Code Green Apparel (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
HIRU
Hiru (PK)
USOTC
CRTG
Coretec (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved